149 related articles for article (PubMed ID: 23609606)
1. In vitro exploration of potential mechanisms of toxicity of the human hepatotoxic drug fenclozic acid.
Rodrigues AV; Rollison HE; Martin S; Sarda S; Schulz-Utermoehl T; Stahl S; Gustafsson F; Eakins J; Kenna JG; Wilson ID
Arch Toxicol; 2013 Aug; 87(8):1569-79. PubMed ID: 23609606
[TBL] [Abstract][Full Text] [Related]
2. Significantly Different Covalent Binding of Oxidative Metabolites, Acyl Glucuronides, and S-Acyl CoA Conjugates Formed from Xenobiotic Carboxylic Acids in Human Liver Microsomes.
Darnell M; Breitholtz K; Isin EM; Jurva U; Weidolf L
Chem Res Toxicol; 2015 May; 28(5):886-96. PubMed ID: 25803559
[TBL] [Abstract][Full Text] [Related]
3. Bioactivation of isothiazoles: minimizing the risk of potential toxicity in drug discovery.
Teffera Y; Choquette D; Liu J; Colletti AE; Hollis LS; Lin MH; Zhao Z
Chem Res Toxicol; 2010 Nov; 23(11):1743-52. PubMed ID: 20825217
[TBL] [Abstract][Full Text] [Related]
4. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose.
Obach RS; Kalgutkar AS; Soglia JR; Zhao SX
Chem Res Toxicol; 2008 Sep; 21(9):1814-22. PubMed ID: 18690722
[TBL] [Abstract][Full Text] [Related]
5. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Morgan RE; van Staden CJ; Chen Y; Kalyanaraman N; Kalanzi J; Dunn RT; Afshari CA; Hamadeh HK
Toxicol Sci; 2013 Nov; 136(1):216-41. PubMed ID: 23956101
[TBL] [Abstract][Full Text] [Related]
6. Identification of the reactive metabolites of fenclozic acid in bile duct cannulated rats.
Martin S; Lenz EM; Keene W; Clench MR
Anal Chem; 2014 Nov; 86(22):11281-9. PubMed ID: 25321605
[TBL] [Abstract][Full Text] [Related]
7. In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam.
Obach RS; Kalgutkar AS; Ryder TF; Walker GS
Chem Res Toxicol; 2008 Sep; 21(9):1890-9. PubMed ID: 18707140
[TBL] [Abstract][Full Text] [Related]
8. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
9. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells.
Ulvestad M; Nordell P; Asplund A; Rehnström M; Jacobsson S; Holmgren G; Davidson L; Brolén G; Edsbagge J; Björquist P; Küppers-Munther B; Andersson TB
Biochem Pharmacol; 2013 Sep; 86(5):691-702. PubMed ID: 23856292
[TBL] [Abstract][Full Text] [Related]
10. Differences in cytochrome P450-mediated biotransformation of 1,2-dichlorobenzene by rat and man: implications for human risk assessment.
Hissink AM; Oudshoorn MJ; Van Ommen B; Haenen GR; Van Bladeren PJ
Chem Res Toxicol; 1996 Dec; 9(8):1249-56. PubMed ID: 8951226
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome p450 inhibitory properties of common efflux transporter inhibitors.
Englund G; Lundquist P; Skogastierna C; Johansson J; Hoogstraate J; Afzelius L; Andersson TB; Projean D
Drug Metab Dispos; 2014 Mar; 42(3):441-7. PubMed ID: 24396142
[TBL] [Abstract][Full Text] [Related]
12. Bioactivation of GPR40 Agonist MK-8666: Formation of Protein Adducts in Vitro from Reactive Acyl Glucuronide and Acyl CoA Thioester.
Shang J; Tschirret-Guth R; Cancilla M; Samuel K; Chen Q; Chobanian HR; Thomas A; Tong W; Josien H; Buevich AV; Mitra K
Chem Res Toxicol; 2020 Jan; 33(1):191-201. PubMed ID: 31566356
[TBL] [Abstract][Full Text] [Related]
13. Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry.
Erve JC; Gauby S; Maynard JW; Svensson MA; Tonn G; Quinn KP
Chem Res Toxicol; 2013 Jun; 26(6):926-36. PubMed ID: 23721565
[TBL] [Abstract][Full Text] [Related]
14. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction.
Bauman JN; Kelly JM; Tripathy S; Zhao SX; Lam WW; Kalgutkar AS; Obach RS
Chem Res Toxicol; 2009 Feb; 22(2):332-40. PubMed ID: 19161298
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse.
Foster JR; Jacobsen M; Kenna G; Schulz-Utermoehl T; Morikawa Y; Salmu J; Wilson ID
Toxicol Pathol; 2012 Dec; 40(8):1106-16. PubMed ID: 22673116
[TBL] [Abstract][Full Text] [Related]
16. Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists.
Kenna JG; Stahl SH; Eakins JA; Foster AJ; Andersson LC; Bergare J; Billger M; Elebring M; Elmore CS; Thompson RA
J Pharmacol Exp Ther; 2015 Feb; 352(2):281-90. PubMed ID: 25467130
[TBL] [Abstract][Full Text] [Related]
17. The potential of Sutherlandia frutescens for herb-drug interaction.
Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
[TBL] [Abstract][Full Text] [Related]
18. Bioactivation of the cannabinoid receptor antagonist rimonabant to a cytotoxic iminium ion metabolite.
Foster AJ; Prime LH; Gustafsson F; Temesi DG; Isin EM; Midlöv J; Castagnoli N; Kenna JG
Chem Res Toxicol; 2013 Jan; 26(1):124-35. PubMed ID: 23234359
[TBL] [Abstract][Full Text] [Related]
19. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.
Funk C; Ponelle C; Scheuermann G; Pantze M
Mol Pharmacol; 2001 Mar; 59(3):627-35. PubMed ID: 11179459
[TBL] [Abstract][Full Text] [Related]
20. NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine.
Zhao SX; Dalvie DK; Kelly JM; Soglia JR; Frederick KS; Smith EB; Obach RS; Kalgutkar AS
Chem Res Toxicol; 2007 Nov; 20(11):1649-57. PubMed ID: 17907785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
